Abstract
In this issue of Blood, Gardner et al report results of a phase 1 trial of 45 children and young adults with relapsed or refractory B-lineage acute lymphoblastic leukemia (ALL) who received a T-cell product of defined CD4/CD8 composition that was genetically modified with a CD19-4-1BB: z chimeric antigen receptor (CAR) lentiviral vector.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 3275-3277 |
| Number of pages | 3 |
| Journal | Blood |
| Volume | 129 |
| Issue number | 25 |
| DOIs | |
| State | Published - Jun 22 2017 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology